Johnson & Johnson completes USD 1 billion acquisition of Firefly Bio

PUBT · 3d ago
Johnson & Johnson completes USD 1 billion acquisition of Firefly Bio
  • Johnson & Johnson completed its acquisition of Firefly Bio for USD 1 billion in cash on July 29, 2026.
  • Deal adds Firefly’s Firelink degrader antibody conjugate platform to expand oncology capabilities, with a focus on hard-to-treat solid tumors.
  • Platform is designed to deliver selective protein degraders to cancer cells, aiming to limit damage to healthy tissue versus existing approaches.
  • Transaction strengthens efforts to target pan-KRAS and other cancer drivers through next-generation antibody engineering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000200406-26-000163), on July 29, 2026, and is solely responsible for the information contained therein.